As of 2024-12-11, the Relative Valuation of Syndax Pharmaceuticals Inc (SNDX) is (96.75) USD. This relative valuation is based on P/E multiples. With the latest stock price at 14.94 USD, the upside of Syndax Pharmaceuticals Inc based on Relative Valuation is -747.6%.
The range of the Relative Valuation is (98.70) - (109.55) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.4x - 45.2x | 35.0x |
| Forward P/E multiples | 19.9x - 31.5x | 20.6x |
| Fair Price | (98.70) - (109.55) | (96.75) |
| Upside | -760.6% - -833.3% | -747.6% |
| Date | P/E |
| 2024-12-10 | -4.29 |
| 2024-12-09 | -4.47 |
| 2024-12-06 | -4.89 |
| 2024-12-05 | -4.83 |
| 2024-12-04 | -4.86 |
| 2024-12-03 | -4.78 |
| 2024-12-02 | -4.80 |
| 2024-11-29 | -4.80 |
| 2024-11-27 | -4.74 |
| 2024-11-26 | -4.74 |
| 2024-11-25 | -4.81 |
| 2024-11-22 | -4.62 |
| 2024-11-21 | -4.48 |
| 2024-11-20 | -4.58 |
| 2024-11-19 | -4.53 |
| 2024-11-18 | -4.63 |
| 2024-11-15 | -4.55 |
| 2024-11-14 | -4.82 |
| 2024-11-13 | -4.78 |
| 2024-11-12 | -4.66 |
| 2024-11-11 | -6.26 |
| 2024-11-08 | -6.27 |
| 2024-11-07 | -6.18 |
| 2024-11-06 | -6.13 |
| 2024-11-05 | -5.66 |
| 2024-11-04 | -5.44 |
| 2024-11-01 | -5.45 |
| 2024-10-31 | -5.42 |
| 2024-10-30 | -5.44 |
| 2024-10-29 | -5.48 |
| 2024-10-28 | -5.52 |
| 2024-10-25 | -5.39 |
| 2024-10-24 | -5.46 |
| 2024-10-23 | -5.33 |
| 2024-10-22 | -5.51 |
| 2024-10-21 | -5.61 |
| 2024-10-18 | -5.66 |
| 2024-10-17 | -5.72 |
| 2024-10-16 | -5.72 |
| 2024-10-15 | -5.68 |
| 2024-10-14 | -5.70 |
| 2024-10-11 | -5.50 |
| 2024-10-10 | -5.23 |
| 2024-10-09 | -5.26 |
| 2024-10-08 | -5.28 |
| 2024-10-07 | -5.25 |
| 2024-10-04 | -5.41 |
| 2024-10-03 | -5.37 |
| 2024-10-02 | -5.59 |
| 2024-10-01 | -5.72 |